Streetbeat News

Products Services

CRLBF

CURLF

GTBIF

TCNNF

VRNOF

Maryland has legalized recreational cannabis sales, with several companies including Green Thumb Industries, Curaleaf Holdings, and Verano Holdings commencing sales at their dispensaries. Green Thumb's RISE Dispensaries also opened a new store in Virginia, while Verano Holdings opened a new store in Florida. Trulieve Cannabis Corp. opened a new store in Georgia, and Cresco Labs opened two new stores in Washington and Pennsylvania.

Portfolio Pulse from Jelena Martinovic

June 30, 2023 | 5:34 pm

General Motors Co (NYSE:GM) has acquired Algolion, an Israel-based software startup that can detect potential hazards in battery cells. The financial terms of the deal were not disclosed. Algolion's software uses data streams from EV battery management systems to identify anomalies in cell performance. The acquisition comes after GM issued two recalls for thousands of Chevrolet Bolt EVs due to battery fire risk.

Portfolio Pulse from Anusuya Lahiri

June 30, 2023 | 5:31 pm

NIO

XPEV

Shares of NIO, Inc. (NYSE:NIO) and XPeng, Inc. (NYSE:XPEV) are trading higher amid strength in Chinese EV names. CLSA upgraded XPeng from a Buy rating to an Outperform rating and raised the price target from $10 to $13.10. XPeng also launched its G6 Ultra Smart Coupe SUV with deliveries expected to begin in July. Nio's shares have gained over 15% in the last week and nearly 30% over the last month after launching its first smart electric tourer, the ET5T.

Portfolio Pulse from Erica Kollmann

June 30, 2023 | 5:25 pm

AMZN

NKE

Nike Inc (NYSE:NKE) saw a significant increase in sales after signing an endorsement deal with Michael Jordan in 1984, leading to the release of Air Jordan shoes in 1985. The shoes quickly became a top seller for the company, with over $55 million in Air Jordans sold by mid-June 1995. Today, Air Jordan is one of the top brands in Nike's portfolio. An investment of $1,000 in Nike stock in 1985 would be worth $791,143.17 today. The story of signing Jordan to a Nike deal became a major motion picture from Amazon.com, Inc. (NASDAQ:AMZN) titled 'Air'.

Portfolio Pulse from Chris Katje

June 30, 2023 | 5:02 pm

AMZN

GOOG

TTD

Amazon is enhancing its ad-buying tools to compete with Google and The Trade Desk. The company is focusing on its demand-side platform (DSP), which uses automation to send targeted ads. Amazon is also targeting 'non-endemic' advertisers, companies that don't sell products through Amazon. The company is also allowing sellers to drive ad traffic to their own direct-to-consumer websites. Amazon, Google, and The Trade Desk are predicted to control about 63% of the DSP market share this year.

Portfolio Pulse from Happy Mohamed

June 30, 2023 | 5:01 pm

PBLA

Panbela Therapeutics has been granted European Patent Number EP3746425 for its lead investigational product SBP-101, used for the treatment of metastatic pancreatic cancer.

Portfolio Pulse from Happy Mohamed

June 30, 2023 | 4:53 pm

BRK-A

BRK-B

BYDDY

NIO

TSLA

XPEV

Chinese automaker Xpeng Inc has priced its G6 SUV below Tesla's Model Y, causing its shares to rally over 12%. This move is expected to boost Xpeng's market share and potentially make the G6 one of the best-selling EVs in China. Meanwhile, Tesla is expected to maintain its leading position with predicted Q2 sales of around 448,350 cars. However, Tesla has been outperformed in China by BYD Company, backed by Warren Buffett's Berkshire Hathaway.

Portfolio Pulse from AJ Fabino

June 30, 2023 | 4:42 pm

ATXG

CNVS

In Friday's mid-day session, several stocks saw significant movement. Addentax Group Corp. (ATXG) shares jumped 47.3% following the launch of an AI internet operational tools project with top Games-as-a-Service firms. Cineverse Corp. (CNVS) fell 17.8% after reporting weak Q4 sales. Other notable movers include CymaBay Therapeutics, Inc. (CBAY), Cyteir Therapeutics, Inc. (CYT), and Renalytix Plc (RNLX).

Portfolio Pulse from Lisa Levin

June 30, 2023 | 4:34 pm

HZNP

Horizon Therapeutics (NASDAQ:HZNP) has announced a new analysis of MRI data from the Phase 3 clinical trial of UPLIZNA, showing a reduction in the formation of subclinical transverse myelitis lesions in people with Neuromyelitis Optica Spectrum Disorder (NMOSD). UPLIZNA is the first and only targeted CD19+ B-cell-depleting therapy approved by the FDA, the European Commission, and the Brazilian Health Regulatory Agency for the treatment of NMOSD in adults. The analysis was presented at the 9th Congress of the European Academy of Neurology.

Portfolio Pulse from Happy Mohamed

June 30, 2023 | 4:31 pm

TEVA

Teva Pharmaceutical Industries Ltd. has announced positive data from the 3rd interim analysis of the pan-European PEARL study on AJOVY® (fremanezumab) for migraine prevention. The data reveals that almost 60% of patients achieved a ≥50% reduction in monthly migraine days, with sustained improvement in disability scores and acute medication use observed over 12 months. The treatment persistence rates were high, with 82.3% of patients remaining on treatment by month 12. The findings will be presented at the European Academy of Neurology Congress 2023.

Portfolio Pulse from Happy Mohamed

June 30, 2023 | 4:31 pm